Answers are grounded in this paper and cite their sources.
We report the case of a patient with mild haemophilia A, due to a Tyr2105Cys mutation in exon 22 of the C1 domain, who developed a high-titre factor VIII inhibitor (maximum titre 1600 BU) with recurrent severe haemorrhages and fatal intracranial bleeding. Based on published data, it appears that although this mutation occurs rarely in patients with mild or moderate haemophilia A, it is frequently associated with the development of high-titre inhibitors.
No takes yet. Share an insight, caveat, or question.
Franchini et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: